
Neuronetics Inc (STIM) Stock Forecast & Price Target
Neuronetics Inc (STIM) Analyst Ratings
Bulls say
Neuronetics is a commercial-stage medical technology company that has performed well despite a decline in treatment session revenue, with positive customer feedback and plans for continued product roll-out. Their recent acquisitions and partnerships have positioned them as a leader in the evolving field of interventional psychiatry, with plans to launch a COMP360 psilocybin therapy and research agreement with Compass. Although there are potential risks, the company has a positive outlook with a Buy rating and $5 price target, backed by a strong customer base and expansion into new markets.
Bears say
Neuronetics is facing a number of challenges, including intense competition in the medical device industry, a shift in the market towards alternative treatment options, and pricing pressures. Additionally, their recent acquisition of Greenbrook TMS has yet to prove profitable and their entry into the psychedelic therapy market with COMP360 may face challenges and delays in obtaining regulatory approval. While the company has shown strong revenues and continued growth, increased operating expenses and potential disruptions in their business model may hinder their profitability in the long term.
This aggregate rating is based on analysts' research of Neuronetics Inc and is not a guaranteed prediction by Public.com or investment advice.
Neuronetics Inc (STIM) Analyst Forecast & Price Prediction
Start investing in Neuronetics Inc (STIM)
Order type
Buy in
Order amount
Est. shares
0 shares